Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate - PubMed (original) (raw)
Clinical Trial
. 2011 Nov;80(10):1073-9.
doi: 10.1038/ki.2011.207. Epub 2011 Jun 29.
Affiliations
- PMID: 21716260
- DOI: 10.1038/ki.2011.207
Free article
Clinical Trial
Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate
Rajiv Agarwal et al. Kidney Int. 2011 Nov.
Free article
Abstract
Vitamin D receptor activation has been associated with increased serum creatinine and reduced estimated glomerular filtration rates, raising concerns that its use may be detrimental to kidney function. Here we studied the effect of vitamin D receptor activation on serum creatinine, creatinine generation, and its clearance. We measured baseline serum creatinine and 24-h urine creatinine in 16 patients with chronic kidney disease. The measurements were repeated every day for 7 days, during which time the patients received 2 μg paricalcitol, an orally active vitamin D receptor activator, every morning. At 4 days after stopping the vitamin analog, measurements were continued for 3 days. Geometric mean parathyroid hormone levels decreased from 77 pg/ml at baseline to 43 pg/ml at the end of treatment and significantly rebounded to 87 pg/ml following paricalcitol withdrawal, thereby supporting the biological efficacy of the analog dose used. With this therapy, the serum creatinine significantly increased at a rate of 0.010 mg/dl/day and urine creatinine at a rate of 17.6 mg/day. Creatinine and iothalamate clearances did not change, whereas urine albumin decreased insignificantly. Thus, short-term vitamin D receptor activation increases creatinine generation and serum creatinine, but it does not influence the glomerular filtration rate.
Trial registration: ClinicalTrials.gov NCT01163162.
Comment in
Similar articles
- Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.
Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Fishbane S, et al. Am J Kidney Dis. 2009 Oct;54(4):647-52. doi: 10.1053/j.ajkd.2009.04.036. Epub 2009 Jul 12. Am J Kidney Dis. 2009. PMID: 19596163 Clinical Trial. - Oral paricalcitol as antiproteinuric agent in chronic kidney disease.
de Lorenzo A, Salanova L, Bomback AS, Moya M, Coronel F, Bernis C, Sánchez-Tomero JA, Álvarez V. de Lorenzo A, et al. Nefrologia. 2013;33(5):709-15. doi: 10.3265/Nefrologia.pre2013.Jun.11928. Nefrologia. 2013. PMID: 24089163 Clinical Trial. - Evaluation of glomerular filtration rate and of albuminuria/proteinuria.
Cirillo M. Cirillo M. J Nephrol. 2010 Mar-Apr;23(2):125-32. J Nephrol. 2010. PMID: 20213606 Review. - Assessment of renal function and progression of disease.
Walser M. Walser M. Curr Opin Nephrol Hypertens. 1994 Sep;3(5):564-7. doi: 10.1097/00041552-199409000-00016. Curr Opin Nephrol Hypertens. 1994. PMID: 7804757 Review.
Cited by
- Pivotal role of vitamin D in mitochondrial health, cardiac function, and human reproduction.
Matta Reddy A, Iqbal M, Chopra H, Urmi S, Junapudi S, Bibi S, Kumar Gupta S, Nirmala Pangi V, Singh I, Abdel-Daim MM. Matta Reddy A, et al. EXCLI J. 2022 Jul 20;21:967-990. doi: 10.17179/excli2022-4935. eCollection 2022. EXCLI J. 2022. PMID: 36110560 Free PMC article. Review. - Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial.
Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH, Lo G, Lai KN, Lo WK, Lam CW, Yu CM. Wang AY, et al. J Am Soc Nephrol. 2014 Jan;25(1):175-86. doi: 10.1681/ASN.2013010103. Epub 2013 Sep 19. J Am Soc Nephrol. 2014. PMID: 24052631 Free PMC article. Clinical Trial. - Renoprotective effects of vitamin D3 supplementation in a rat model of metabolic syndrome.
Wahba NS, Ghareib SA, Abdel-Ghany RH, Abdel-Aal M, Alsemeh AE. Wahba NS, et al. Eur J Nutr. 2021 Feb;60(1):299-316. doi: 10.1007/s00394-020-02249-6. Epub 2020 Apr 22. Eur J Nutr. 2021. PMID: 32322970 - Metabolomics and Gene Expression Analysis Reveal Down-regulation of the Citric Acid (TCA) Cycle in Non-diabetic CKD Patients.
Hallan S, Afkarian M, Zelnick LR, Kestenbaum B, Sharma S, Saito R, Darshi M, Barding G, Raftery D, Ju W, Kretzler M, Sharma K, de Boer IH. Hallan S, et al. EBioMedicine. 2017 Dec;26:68-77. doi: 10.1016/j.ebiom.2017.10.027. Epub 2017 Oct 31. EBioMedicine. 2017. PMID: 29128444 Free PMC article. - Low Sodium Diet, Vitamin D, or Both for RAASi-Resistant, Residual, Proteinuria in CKD? The ViRTUE Trial Points the Way Forward but Is Not the Last Word.
Goldsmith D, Thadhani RI. Goldsmith D, et al. J Am Soc Nephrol. 2017 Apr;28(4):1016-1019. doi: 10.1681/ASN.2016121321. Epub 2017 Feb 28. J Am Soc Nephrol. 2017. PMID: 28246129 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical